Key result
Treatment with rivaroxaban successfully resolved leaflet thrombosis and reduced the mean trans-aortic valve pressure gradient from 48 mmHg to 17 mmHg in a patient with worsening heart failure after TAVR.
Why the study?
Few reports are available on managing leaflet thrombosis after TAVR presenting with worsening heart failure.
Does rivaroxaban resolve leaflet thrombosis and improve valve hemodynamics in a patient with worsening heart failure post-TAVR?
Case Report (n=1)
Does rivaroxaban resolve leaflet thrombosis and improve valve hemodynamics in a patient with worsening heart failure post-TAVR?
NOAC therapy (rivaroxaban) successfully resolved clinical leaflet thrombosis and normalized valve hemodynamics in a patient presenting with worsening heart failure one year after TAVR.
May warrant CT for unexplained HF or rising gradient after TAVR; leaves open NOAC for clinical leaflet thrombosis.
Background: Transcatheter aortic valve replacement (TAVR) is indicated for treating symptomatic severe aortic valve stenosis (AS) with intermediate-to-high surgical risks. Few reports are available on managing leaflet thrombosis after TAVR with worsening heart failure. Case Summary: A 77-year-old man with severe AS and coronary artery disease (CAD) received a successful TAVR with Edwards Sapien 3 valve. A year later, the patient developed a worsening heart failure with pulmonary edema, new-onset atrial fibrillation (Af), an increase in mean trans-aortic valve pressure gradient to 48 mmHg, worsening mitral regurgitation (MR), and pulmonary hypertension (PH). The response of the patient to intravenous diuretics and inotropic treatments was poor. Multi-slice CT (MDCT) revealed hypo-attenuated thrombus and thickened transcatheter heart valve leaflets. A non-vitamin K antagonist oral anti-coagulant (NOAC) was added to treat the new-onset Af and leaflet thrombosis on top of the con-current single antiplatelet for CAD. A series of follow-up echocardiograms showed a progressive decrease in trans-aortic valve pressure gradient to 17 mmHg and reductions in MR and PH. Three months after the NOAC treatment, MDCT revealed the resolution of hypo-attenuated thrombus and thickened leaflets. Symptoms of heart failure were also improved gradually. Discussion: Worsening heart failure or an increase in trans-aortic valve pressure gradient after TAVR warranted further MDCT studies. Leaflet thrombosis can be resolved after using NOAC as in our present case.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2021) conducted a case report in Leaflet thrombosis after TAVR (n=1). Rivaroxaban (NOAC) was evaluated on Resolution of leaflet thrombosis and trans-aortic valve pressure gradient. Treatment with rivaroxaban successfully resolved leaflet thrombosis and reduced the mean trans-aortic valve pressure gradient from 48 mmHg to 17 mmHg in a patient with worsening heart failure after TAVR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: